Natriuretic peptide-guided versus clinically guided therapy for chronic heart failure: careful expert clinical management can remove need for biomarker-tailored dosing adjustment.
作者信息
De Vecchis Renato
机构信息
Cardiology Unit, Presidio Sanitario Intermedio "Elena d'Aosta", Napoli, Italy.
出版信息
J Thorac Dis. 2017 Nov;9(11):4137-4140. doi: 10.21037/jtd.2017.10.26.
Abstract
摘要
相似文献
1
Natriuretic peptide-guided versus clinically guided therapy for chronic heart failure: careful expert clinical management can remove need for biomarker-tailored dosing adjustment.
J Thorac Dis. 2017 Nov;9(11):4137-4140. doi: 10.21037/jtd.2017.10.26.
2
B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):122-34. doi: 10.2459/JCM.0b013e328364bde1.
3
The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use.
Arch Cardiovasc Dis. 2012 Jan;105(1):40-50. doi: 10.1016/j.acvd.2011.10.007. Epub 2012 Jan 16.
4
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.
J Am Coll Cardiol. 2009 Dec 29;55(1):53-60. doi: 10.1016/j.jacc.2009.02.095.
5
Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
Am Heart J. 2009 Sep;158(3):422-30. doi: 10.1016/j.ahj.2009.06.018. Epub 2009 Jul 9.
6
Biomarker-guided treatment of congestive heart failure.
Congest Heart Fail. 2010 Jul;16 Suppl 1:S62-7. doi: 10.1111/j.1751-7133.2010.00169.x.
7
NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
Circulation. 2018 Apr 17;137(16):1671-1683. doi: 10.1161/CIRCULATIONAHA.117.029882. Epub 2017 Dec 14.
8
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18.
9
Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
J Card Fail. 2012 Aug;18(8):626-34. doi: 10.1016/j.cardfail.2012.05.005. Epub 2012 Jun 19.
10
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Eur J Heart Fail. 2013 Oct;15(10):1148-56. doi: 10.1093/eurjhf/hft076. Epub 2013 May 8.
本文引用的文献
1
Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
JAMA. 2017 Aug 22;318(8):713-720. doi: 10.1001/jama.2017.10565.
2
An Admission-to-Discharge BNP Increase Is a Predictor of Six-Month All-Cause Death in ADHF Patients: Inferences from Multivariate Analysis Including Admission BNP and Various Clinical Measures of Congestion.
J Clin Med. 2016 Nov 10;5(11):99. doi: 10.3390/jcm5110099.
3
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20.
4
The predictive value of plasma biomarkers in discharged heart failure patients: the role of plasma BNP.
Minerva Cardioangiol. 2016 Apr;64(2):147-56. Epub 2015 Oct 16.
5
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Circulation. 2013 Oct 15;128(16):e240-327. doi: 10.1161/CIR.0b013e31829e8776. Epub 2013 Jun 5.
6
Natriuretic peptide-guided therapy: further research required for still-unresolved issues.
Herz. 2013 Sep;38(6):618-28. doi: 10.1007/s00059-013-3772-8. Epub 2013 Apr 17.
7
Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
J Card Fail. 2012 Aug;18(8):626-34. doi: 10.1016/j.cardfail.2012.05.005. Epub 2012 Jun 19.
8
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study.
J Am Coll Cardiol. 2010 Dec 14;56(25):2090-100. doi: 10.1016/j.jacc.2010.07.030.
9
Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study--Guidelines and NT-proBNP AnaLysis in Heart Failure).
Eur J Heart Fail. 2010 Dec;12(12):1300-8. doi: 10.1093/eurjhf/hfq169. Epub 2010 Sep 28.
10
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial.
J Am Coll Cardiol. 2009 Dec 29;55(1):53-60. doi: 10.1016/j.jacc.2009.02.095.
Zotero 插件